Open access
Aug 2026
Mut-p53 acts as a synthetic lethal partner with E2F3 inhibition in gastric cancer under FGFR1 inhibitor.
BACKGROUND Gastric cancer frequently harbors TP53 mutations, posing a challenge for therapies directly targeting mutant p53. Fibroblast growth factor receptor 1 (FGFR1) is a potential therapeutic target, but its interaction with mutant p53 in gastric cancer remains poorly understood. METHODS We evaluated our newly de...
Si-Jia Zhong, Fanxi Meng, Leyu Wan et al.
· Cellular Signalling · 0 citations